FDA approves 1st-of-its-kind kidney disease treatment
The FDA has granted accelerated approval to Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression, making it the first and only C5 complement inhibitor approved for this use. The approval followed Priority Review and was based on a prespecified interim analysis of the I CAN phase […] The post FDA approves 1st-of-its-kind kidney disease treatment appeared first on Becker's Hospital Review | Healthcare News &...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.